Latest Health News

Singular Health Group has advanced its US expansion through the deployment of 3DICOM™ licenses under a key contract with Provider Network Solutions, alongside appointing a new US commercial chief to drive growth.

Race Oncology showcased compelling preclinical data at ESMO 2025 revealing that their drug RC220, combined with doxorubicin, not only shields the heart from toxicity but also boosts anticancer effects, supporting ongoing clinical trials.

DroneShield Limited has delivered a blockbuster quarter with record revenue and operating cash flow, driven by new SaaS products and major government contracts. The company is positioning itself for sustained profitability and expansion into civilian markets.

BCAL Diagnostics has established a $10 million convertible note facility, with $5 million already committed, to accelerate its cancer detection technologies and commercial milestones.

DGL Group Limited remains suspended from ASX trading following delays in lodging audited accounts and a concerning auditor disclaimer. Investors await clarity on the company’s financial health and path to reinstatement.

PWR Holdings announces a pivotal leadership transition alongside the completion of its new global headquarters, reporting a transitional FY25 with mixed financial results but a confident outlook for FY26.

AVITA Medical has appointed Board Chairman Cary Vance as Interim CEO following Jim Corbett's departure, while preliminary third-quarter revenue is expected to reach approximately $17 million.

Biome Australia Limited has reported a record quarterly revenue of $5.94 million for Q1 FY26, marking a 40% increase year-over-year and its seventh consecutive quarter of positive EBITDA. The company’s strong cash flow and sustained margins underscore its growth momentum.

Fiducian Group Limited has voluntarily released its Appendix 4C for Q3 2025, reporting steady net inflows to its core platform and a rise in total funds under management to $15.6 billion.

Alcidion Group Limited has reported a record FY25 with strong revenue growth, major NHS contract wins, and expanded AI capabilities in its Miya Precision platform, setting the stage for global healthcare IT expansion.

Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.